Home/Filings/4/0001439222-24-000050
4//SEC Filing

Washburn Theodore James Jr. 4

Accession 0001439222-24-000050

CIK 0001439222other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 4:15 PM ET

Size

16.8 KB

Accession

0001439222-24-000050

Insider Transaction Report

Form 4
Period: 2024-03-01
Washburn Theodore James Jr.
Principal Accounting Officer
Transactions
  • Exercise/Conversion

    Common stock

    2024-03-01+7773,663 total
  • Sale

    Common stock

    2024-03-05$32.57/sh295$9,6083,368 total
  • Exercise/Conversion

    Common stock

    2024-03-01+2,3505,718 total
  • Sale

    Common stock

    2024-03-05$32.57/sh919$29,9324,799 total
  • Award

    Restricted stock units

    2024-03-01+7,3507,350 total
    Common stock (7,350 underlying)
  • Exercise/Conversion

    Restricted stock units

    2024-03-01777777 total
    Common stock (777 underlying)
  • Exercise/Conversion

    Restricted stock units

    2024-03-012,3504,700 total
    Common stock (2,350 underlying)
Footnotes (7)
  • [F1]Includes 752 shares purchased through the Company's employee stock purchase plan.
  • [F2]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2022.
  • [F3]Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
  • [F4]Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
  • [F5]The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F6]The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
  • [F7]The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.

Issuer

AGIOS PHARMACEUTICALS, INC.

CIK 0001439222

Entity typeother

Related Parties

1
  • filerCIK 0001874199

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:15 PM ET
Size
16.8 KB